Roche's Genentech is launching a direct-to-consumer program for its flu pill, Xofluza, offering it at a 70% discount ($50 cash pay) through select pharmacies including Amazon Pharmacy and Mark Cuban's Cost Plus Drug Company. This strategic move aims to expand access for uninsured or underinsured patients ahead of the flu season and aligns with broader pharmaceutical industry trends, driven by government pressure to lower U.S. drug prices, following similar actions by other major drugmakers.
Roche's Genentech is implementing a direct-to-consumer (DTC) program for its flu antiviral, Xofluza, offering it at a 70% discount, or $50 cash pay, through select pharmacies including Amazon Pharmacy and Mark Cuban's Cost Plus Drug Company. This initiative aims to broaden access for uninsured or underinsured patients, strategically launching ahead of the upcoming flu season, following the severe 2024-2025 season. This move aligns with a broader industry trend where pharmaceutical companies are adopting DTC models, partly in response to government pressure to lower U.S. drug prices. The Trump administration specifically urged 17 drugmakers to curb costs, with Pfizer and AstraZeneca having already established similar agreements. Genentech's existing coupon program, offering Xofluza for as little as $35, further underscores its multi-faceted approach to patient access. The discounted offering and expanded distribution channels, including same-day and mail delivery options, could significantly increase Xofluza's market penetration, particularly among price-sensitive consumers. This strategy reflects a proactive adaptation to evolving market demands and regulatory scrutiny within the pharmaceutical sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
